A world-leading biomedical ecosystem has taken shape in BioBAY, and the enterprises in it are developing fast. Last month, three companies in BioBAY brought good news.
SA Biotech (Suzhou) Pte Ltd, a wholly-owned subsidiary of Advaccine Biotech (Suzhou) Co Ltd, an innovative vaccine developer, received the permit for manufacturing “biological products for prevention”, becoming the first biopharmaceutical company in Suzhou to get the permit.
In the same month, Suzhou Industrial Park Biotech Development Co Ltd, operator of BioBAY, and its partners launched the country’s first biomedicine cluster-based REIT (real estate investment trust) project at Shanghai Stock Exchange.
Concurrently, Innovent Biologics, a biotech unicorn in BioBAY, and its partner Eli Lilly and Company announced that the US Food and Drug Administration accepted for review a Biologics License Application for Sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC). It is the first US regulatory submission of Sintilimab, a PD-1 inhibitor being developed and commercialized by Innovent and Eli Lilly.
